Skip to main content
Premium Trial:

Request an Annual Quote

Atreca, A*Star Genome Institute Establish Joint Lab for Immuno-Oncology

NEW YORK (GenomeWeb) – Drug developer Atreca and Singapore's Agency for Science, Technology, and Research (A*Star) said today that they have begun a collaboration that will advance Atreca's high-throughput, microfluidic technology to support discovery and development of immuno-oncology therapeutics.

Funded by both parties, the effort will establish a joint laboratory at A*Star's Genome Institute of Singapore, where the collaborators will work on enhancements to Atreca's microfluidic technology for next-generation sequencing of single cells.

More specifically, the partners plan to develop the platform for identification of genes associated with antibodies and T cell receptors, as well as those in B and T cells that play important roles in directing the body's immune response to cancer.

The hope is that the ability to analyze these genes can pave the way for more targeted and effective immunotherapies.

Yann Chong Tan, cofounder of Atreca and an A*Star scholar, will head the new Atreca-GIS joint lab.